Zoetis investors now face a hard deadline: July 27, 2026. That is the last day to contact the Schall Law Firm if you bought shares between January 14, 2025, and May 6, 2026. The firm has already filed a class action lawsuit.
The claim is that the company lied to the market during that stretch. The lawsuit homes in on one medication: Librela.
That drug treats pain in dogs. The FDA issued safety warnings about neurological complications. After that, veterinarian prescription growth for Librela weakened.
That is the core fact the lawsuit hangs on. But Librela was not the only problem.
The lawsuit also points to Zoetis losing market share on its Trio product. And on Apoquel and Cytopoint, its dermatology drugs for dogs. Taken together, these failures made the company’s public statements false and misleading, according to the filing.
Zoetis is a big animal health company. It trades on the NYSE as ZTS. The Schall Law Firm is a national shareholder rights litigation firm based in Los Angeles.
Brian Schall founded it. He is the contact: 310-301-3335, or the firm’s website at www.schallfirm.com.
Here is the legal mechanism. The lawsuit alleges violations of the Securities Exchange Act of 1934. That law requires publicly traded companies to tell the truth to investors.
The complaint says Zoetis did not do that. The company’s statements were materially misleading, the lawsuit claims.
That means a reasonable investor would have cared about the omitted or false information. The timeline matters. The Class Period starts January 14, 2025.
That is when the alleged false statements began. It ends May 6, 2026. That is when the truth presumably came out.
Anyone who bought ZTS stock in that window has a potential claim. The Schall Law Firm is actively recruiting investors to join the lawsuit.
They want to hear from people before the July 27 deadline. That is likely a court-ordered cut-off for lead plaintiff motions. If you bought shares, you should call them.
They will explain the details and how the case might affect you. This is a straightforward securities fraud allegation.
The company said things about its business that were not true. The lawsuit lays out specific products and specific problems. Librela’s prescription growth stalled after the FDA warning.
Trio lost market share. Apoquel and Cytopoint lost market share. Those are concrete business facts.
The company’s public statements did not reflect those facts, the lawsuit says. Investors made decisions based on what Zoetis told them.
If those statements were false, investors may have paid too much for the stock. That is the theory of the case. The lawsuit will now proceed through the federal court system.
Discovery will happen. Documents will be produced.
Depositions will be taken. For now, the clock is ticking. July 27, 2026, is the cutoff.
The Schall Law Firm has made itself available. Brian Schall is the person to call. 310-301-3335. Or go to the website.
The firm says it is worth contacting them to understand the lawsuit and how it may affect investors.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Zoetis Investors Face July 2026 Deadline in Librela Lawsuit”, “description”: “Zoetis investors now face a hard deadline: July 27, 2026. That is the last day to contact the Schall Law Firm if you bought shares…”, “datePublished”: “2026-06-22T13:10:00+00:00T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Noah King”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
